Think of Verquvo as a "Niche" Med for Heart Failure

April 2021

Reps will tout Verquvo (vericiguat) as a new once-daily add-on for worsening heart failure with reduced ejection fraction (HFrEF).

Verquvo is the first "soluble guanylate cyclase stimulator" for HFrEF. It relaxes blood vessels through the nitric oxide pathway.

Most evidence is in patients already on triple therapy...an ACEI, ARB, or Entresto (sacubitril/valsartan), beta-blocker (carvedilol, etc), AND aldosterone antagonist (spironolactone, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote